ARIMIDEX
Pronunciation: an-AS-troe-zoel


What it isAromatase inhibitor blocking peripheral estrogen synthesis; hormone receptor-positive breast cancer in postmenopausal women.
Why this oneUnlike steroidal exemestane, it is reversible and nonsteroidal; it lacks tamoxifen's endometrial-cancer and thrombosis liabilities.
What limits itAccelerated bone loss and arthralgia; monitor density. It is ineffective before menopause unless ovarian function is suppressed.
Animated chart of estimated U.S. prescriptions per year, Oral anticancer meds (1953–2026). Anastrozole enters in 1996 (estimated).
Principal riskAccelerated bone loss and arthralgia
Legacy pregnancy categoryMultiple / indication-, trimester- or formulation-dependent
Defining liabilityThrombotic, metabolic, hepatic, skeletal or reproductive toxicity varies by hormonal target.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Breast cancer (adjuvant early-stage, or advanced) in postmenopausal women | Postmenopausal women | 1 mg QD | 1 mg QD | 1 mg QD |
Renal No adjustment needed
Hepatic Mild-to-moderate impairment: no change; severe impairment: not studied.
Available strengths
Pregnancy May cause fetal harm based on animal findings and mechanism of action; embryo-fetal toxicities in rats; advise effective contraception.
Lactation No data on presence in human milk; because of tumorigenicity in animal studies, breastfeeding is not recommended.
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 1 mg | tab | 30 qd | $4.25 | offered |
Generic entry2010
Open Anastrozole in the interactive console ↗